EyRIS, a pioneering company in artificial intelligence (AI) healthcare solutions, and Optometrist Warehouse which is part of the Chemist Warehouse Group in Australia, have inked a memorandum of understanding (MOU) to collaborate on a ground-breaking study focused on the effectiveness of AI (artificial intelligence) in screening diabetic retinopathy.
This collaboration marks a significant milestone in the field of healthcare by showcasing the potential benefits of AI-driven solutions in improving patient outcomes and cost-effectiveness.
Diabetic retinopathy, a common complication of diabetes, is a leading cause of blindness among adults globally.
According to the Australian Diabetes Society, over 1.5 million Australians are currently living with diabetes with this number projected to increase significantly over the next decade. Early detection and intervention are crucial to prevent vision loss and related complications.
The study will leverage EyRIS’s advanced AI algorithms and Optometrist Warehouse expertise with links to the extensive network of pharmacies across Australia of Chemist Warehouse to evaluate the effectiveness of AI-driven screening for diabetic retinopathy.
By using EyRIS’s cutting-edge technology which analyses retinal images for signs of diabetic retinopathy, the study aims to demonstrate the efficacy and efficiency of AI in identifying patients at risk and facilitating early intervention.
“We are thrilled to partner with Optometrist Warehouse on this ground-breaking study. By harnessing the power of AI, we can revolutionise diabetic retinopathy screening, ensuring early detection and timely treatment for patients,” commented EyRIS’ CEO Lai Teik Kin,
“Our technology has the potential to transform healthcare delivery, saving lives and reducing healthcare costs.”
With an innovative mission to transforming health outcomes by systematically connecting pharmacy with optometry, Optometrist Warehouse’s managing director Peter Larsen said the company recognises the transformative impact of AI in the field of medicine.
“We are proud to collaborate with EyRIS to explore the possibilities of AI in diabetic retinopathy screening,” he acknowledged.
“This study aligns with our mission to improve healthcare outcomes for all Australians. By leveraging EyRIS’s AI expertise, we can enhance the accessibility and affordability of early screening, thereby empowering patients and healthcare providers alike.”
The collaboration between EyRIS and Optometrist Warehouse underscores the commitment of both organisations to leverage technological advancements for the betterment of healthcare.
The potential benefits of AI-driven diabetic retinopathy screening include reducing the burden on healthcare systems, minimising unnecessary referrals, and enabling targeted interventions, ultimately improving patient outcomes.
The study will span a period of 36 months and involve a large sample size of diabetic patients across various regions in Australia. – June 1, 2023
